Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma. The second area is to develop novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma, assess their potential correlation with clinical outcomes and as therapeutic targets, and dissect the molecular mechanisms of drug resistance to targeted therapy.
As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he led early efforts of developing several molecularly targeted and immunotherapy agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers. He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of ASCO and AACR. Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Cancer Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.